Illumina (NASDAQ:ILMN) Cut to “Hold” at Wall Street Zen

Wall Street Zen cut shares of Illumina (NASDAQ:ILMN) from a buy rating to a hold rating in a research report sent to investors on Saturday,Wall Street Zen reports.

ILMN has been the subject of a number of other research reports. Argus raised their price target on shares of Illumina from $180.00 to $235.00 and gave the stock a “buy” rating in a research note on Thursday, September 3rd. UBS Group upgraded Illumina from a “neutral” rating to a “buy” rating and upped their price objective for the company from $135.00 to $260.00 in a research note on Wednesday, September 9th. Canaccord Genuity Group increased their target price on Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a report on Monday, August 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Illumina in a research report on Monday, August 31st. Finally, Piper Sandler boosted their price target on Illumina from $225.00 to $305.00 and gave the company an “overweight” rating in a research note on Monday, September 28th. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $219.69.

Illumina Stock Up 7.6%

ILMN opened at $293.69 on Friday. The company has a market capitalization of $44.35 billion, a P/E ratio of 54.79, a P/E/G ratio of 3.87 and a beta of 1.41. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The firm’s fifty day moving average price is $221.46 and its two-hundred day moving average price is $177.17. Illumina has a fifty-two week low of $88.00 and a fifty-two week high of $296.25.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter in the prior year, the company posted $1.19 EPS. The business’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts anticipate that Illumina will post 5.36 EPS for the current year.

Insider Buying and Selling

In other Illumina news, SVP Christensen Wedel sold 1,033 shares of Illumina stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president owned 14,023 shares in the company, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 119,501 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $218.40, for a total value of $26,099,018.40. Following the sale, the director owned 770,350 shares in the company, valued at $168,244,440. The trade was a 13.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 2,061,850 shares of company stock worth $436,479,102. 2.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Baker Tilly Wealth Management LLC lifted its position in Illumina by 3.3% during the third quarter. Baker Tilly Wealth Management LLC now owns 1,297 shares of the life sciences company’s stock valued at $355,000 after purchasing an additional 42 shares during the period. Elevation Wealth Partners LLC raised its stake in Illumina by 52.5% in the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after purchasing an additional 84 shares during the last quarter. Meeder Advisory Services Inc. grew its position in shares of Illumina by 3.1% in the first quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after purchasing an additional 85 shares in the last quarter. Gabelli Funds LLC increased its stake in shares of Illumina by 2.0% in the 1st quarter. Gabelli Funds LLC now owns 5,000 shares of the life sciences company’s stock worth $616,000 after acquiring an additional 100 shares during the last quarter. Finally, MCF Advisors LLC raised its stake in Illumina by 172.4% during the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 100 shares during the period. 89.42% of the stock is owned by institutional investors.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Royal Bank of Canada raised its price target for Illumina from $230 to $310 and maintained an “outperform” rating. The revised target implies additional upside from the stock’s current level and helped support buying momentum. Royal Bank Of Canada Issues Positive Forecast for Illumina Stock Price
• Positive Sentiment: RBC also characterized Illumina’s clinical sequencing revenue as a durable mid-teens growth business, reinforcing expectations for sustained demand for sequencing instruments, consumables and related services. Illumina’s Clinical Sequencing Revenue Seen as Durable Mid-Teens Grower
• Positive Sentiment: Illumina reached a new one-year high following the analyst upgrade, indicating strong market momentum. The move follows recent increases to analyst targets, the company’s higher 2026 guidance, and its addition to the S&P 500, which can increase demand from index-tracking funds. Illumina Sets New One-Year High on Analyst Upgrade
• Neutral Sentiment: The rally appears driven primarily by follow-through from earlier catalysts rather than a new earnings release. Illumina’s latest reported quarter exceeded consensus estimates for revenue and adjusted earnings, while full-year 2026 guidance was raised.
• Negative Sentiment: Quiver Quantitative data shows substantial insider selling over the past six months, with no reported open-market purchases. This may signal profit-taking or create a valuation overhang, particularly after the stock’s sharp advance.

About Illumina

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.